8-K: MannKind Reports Strong Q3 2025 Revenue Growth, Pipeline Advances

MannKind Corporation announced robust third-quarter 2025 financial results, including a 17% revenue increase, alongside significant progress in its product pipeline and the completion of the scPharmaceuticals acquisition.

Summary

• Q3 2025 revenues reached $82.1 million, a 17% increase compared to Q3 2024.
• Year-to-date 2025 revenues were $237.0 million, up 14% from YTD 2024.
• Completed the acquisition of scPharmaceuticals on October 7, 2025, which is expected to accelerate revenue growth with FUROSCIX.
• The FDA accepted for review the sBLA for Afrezza in the pediatric population (aged 4-17 years), with a PDUFA date of May 29, 2026.
• Submitted the FUROSCIX ReadyFlow Autoinjector sNDA to the FDA, with a review acceptance decision expected by year-end 2025.
• The MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved its interim enrollment target of 100 patients ahead of schedule, with interim analysis expected mid-2026.
• Initiated the MNKD-201 IPF Phase 2 trial (INFLO) and expects to enroll the first patient in Q1 2026.
• Q3 2025 GAAP net income was $8.0 million ($0.03 EPS basic), down from $11.6 million ($0.04 EPS basic) in Q3 2024.
• Q3 2025 non-GAAP net income was $22.4 million ($0.07 EPS basic), up from $15.4 million ($0.06 EPS basic) in Q3 2024.
• Cash, cash equivalents, and investments totaled $286.3 million as of September 30, 2025.
• Utilized approximately $133.2 million of available cash and borrowed an additional $250.0 million in delayed draw term loans in October 2025 to fund the scPharmaceuticals acquisition and related debt extinguishment.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, particularly in key products and royalties, and made significant progress on its pipeline and strategic acquisition. While GAAP net income declined due to an impairment and acquisition costs, non-GAAP net income showed robust growth. The successful integration of scPharmaceuticals and multiple regulatory/clinical milestones indicate strong operational execution and future growth potential.

Positives

• Total revenues increased by 17% to $82.1 million in Q3 2025 and 14% to $237.0 million YTD 2025.
• Royalties grew 23% in Q3 2025 and 26% YTD 2025, driven by increased net sales of Tyvaso DPI.
• Afrezza commercial product revenue increased 23% in Q3 2025 to $18.5 million, mainly due to higher price and demand.
• Successful acquisition of scPharmaceuticals completed on October 7, 2025, expected to diversify and accelerate double-digit revenue growth with FUROSCIX.
• FDA accepted Afrezza pediatric sBLA for review, with a PDUFA date set for May 29, 2026.
• FUROSCIX ReadyFlow Autoinjector sNDA submitted as planned.
• MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved interim enrollment target of 100 patients ahead of schedule.
• Initiated MNKD-201 IPF Phase 2 trial (INFLO).
• Non-GAAP net income increased by 45% to $22.4 million in Q3 2025 and 30% to $58.0 million YTD 2025.
• Appointed Dr. Ajay Ahuja as Chief Medical Officer.

Negatives

• V-Go net revenue decreased by 19% in Q3 2025 to $3.8 million and 11% YTD 2025 due to lower demand.
• GAAP net income decreased by $3.6 million to $8.0 million in Q3 2025 compared to Q3 2024.
• Impairment of available-for-sale investment of $6.4 million in Q3 2025 due to the write-off of the Thirona investment.
• Loss on foreign currency transactions was $7.8 million for the nine months ended September 30, 2025, compared to a loss of $0.5 million for the same period in the prior year.

Risks

• Risks and uncertainties associated with competition.
• Commercial execution challenges.
• Regulatory changes impacting the pharmaceutical, medical device, and healthcare industries.
• Challenges in developing product candidates.
• Unforeseen delays that may impact the timing of clinical trials and reporting data.
• Regulatory review process risks.
• Manufacturing risks.
• Intellectual property protection challenges.
• Personnel-related risks.
• Macroeconomic and geopolitical factors.

Future Outlook

MannKind expects to accelerate revenue growth through the scPharmaceuticals acquisition and FUROSCIX. The company anticipates regulatory decisions for Afrezza pediatric sBLA by May 29, 2026, and for the FUROSCIX ReadyFlow Autoinjector sNDA by year-end 2025. Clinical trials for MNKD-101 and MNKD-201 are progressing, with an interim analysis for ICoN-1 expected mid-2026 and first patient enrollment for INFLO in Q1 2026. The company is also formulating a second dry powder investigational molecule and planning a Bumetanide DPI pre-clinical study.

Management Comments

• "The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies." Michael Castagna, PharmD, Chief Executive Officer.
• "With the FDAs acceptance for review of the Afrezza pediatric sBLA, the submission of the FUROSCIX ReadyFlow Autoinjector sNDA, and continued progress in the pipeline programs, we are executing across a diversified portfolio with significant growth opportunities ahead." Michael Castagna, PharmD, Chief Executive Officer.

Industry Context

The biopharmaceutical industry continues to see strategic M&A activity, as evidenced by MannKind's acquisition of scPharmaceuticals to expand its commercial footprint and diversify its revenue streams. The focus on innovative drug-device combinations and patient-centric therapies for chronic diseases like diabetes, pulmonary hypertension, heart failure, and chronic kidney disease aligns with broader industry trends towards specialized treatments and improved drug delivery. The progress in clinical trials for NTM and IPF also reflects ongoing efforts to address orphan lung diseases.

Management Changes

Related Party Transactions

• Royalties earned on increased net sales of Tyvaso DPI (trademark of United Therapeutics Corporation).
• Higher revenue from collaborations and services due to increased product sold to United Therapeutics Corporation (UT).
• MannKind's co-promotion agreement with Amphastar.
• Under the Company's Insulin Supply Agreement with Amphastar, payment obligations for future purchases are denominated in Euros.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, pipeline progress, and strategic acquisition, potentially leading to increased share value. Dilution from increased shares (306,806k basic Q3 2025 vs 274,998k basic Q3 2024) might be a consideration.
• Patients: Potential for new and improved therapies (Afrezza pediatric, FUROSCIX ReadyFlow Autoinjector, MNKD-101, MNKD-201) addressing unmet medical needs in diabetes, heart failure, chronic kidney disease, NTM, and IPF.
• Employees: Increased headcount and personnel-related costs suggest growth and potential for new roles, especially with the scPharmaceuticals acquisition and expansion of medical science liaison team.
• Creditors: Increased debt ($250.0 million delayed draw term loans) to fund the acquisition, which will need to be serviced.
• United Therapeutics: Continued collaboration and royalty payments for Tyvaso DPI.
• Amphastar: Ongoing co-promotion agreement and insulin supply agreement.

Next Steps

• Discussion of full pediatric study results for Afrezza (including safety extension) at the International Society for Pediatric and Adolescent Diabetes meeting, November 5-8, 2025.
• Review acceptance decision for FUROSCIX ReadyFlow Autoinjector sNDA by year-end 2025.
• Decision on Afrezza labeling update expected Q1 2026.
• Enrollment of first patient in MNKD-201 IPF Phase 2 trial (INFLO) in Q1 2026.
• Interim analysis (study sample size re-estimation) for MNKD-101 NTM global Phase 3 trial (ICoN-1) expected mid-2026.
• Formulating a second dry powder investigational molecule under expanded collaboration with United Therapeutics.
• Planned Bumetanide DPI pre-clinical study.

Key Dates

Recommendation

The filing demonstrates strong operational execution and strategic growth. The 17% revenue increase, significant non-GAAP net income growth, and successful integration of scPharmaceuticals are key positives. The advancement of multiple pipeline assets, including FDA acceptance for Afrezza pediatric use and the MNKD-101 trial progressing ahead of schedule, de-risks future growth. While GAAP net income saw a temporary dip due to an impairment and acquisition costs, the underlying business momentum and strategic expansion into new therapeutic areas with FUROSCIX present a compelling long-term growth story. The company is actively expanding its commercial capabilities and product portfolio, which should drive sustained revenue and earnings growth.

Keywords

MannKind, MNKD, Q3 2025, financial results, Afrezza, FUROSCIX, scPharmaceuticals, NTM, IPF, MNKD-101, MNKD-201, insulin, pulmonary hypertension, heart failure, chronic kidney disease, biopharmaceutical, drug-device combinations, Technosphere